Skip to content

Canceled by the investigator. Protective effect of Fospropofol Disodium on Hepatic ischemia-reperfusion injury in patients undergoing laparoscopic anatomical hepatectomy

Protective effect of Fospropofol Disodium on Hepatic ischemia-reperfusion injury in patients undergoing laparoscopic anatomical hepatectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101251
Enrollment
Unknown
Registered
2025-04-22
Start date
2025-05-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic ischemia-reperfusion injury

Interventions

Group P:Propofol
Group FP:Fospropofol Disodium

Sponsors

The First People's Hospital of Zhaoqing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age between 40-75 years old, ASA score II.-III., BMI19~28 kg/m^2, gender is not limited; 2. The patient meets the medical criteria for liver surgery; 3. The patient or his/her legal representative has signed an informed consent form; 4. The patient has not participated in other clinical trials; 5. No communication disorder, no history of psychiatric or neurological disease; 6. No history of long-term use of sedative drugs; 7. No history of drug allergies.

Exclusion criteria

Exclusion criteria: 1. Severe heart, lung, liver, or kidney disease. 2. Alcohol or drug abuse history. 3. Pregnant or breastfeeding. 4. Liver tumor rupture or blood disorders.

Design outcomes

Primary

MeasureTime frame
ALT;AST;Bilirubin;

Secondary

MeasureTime frame
SOD;MDA;TNF-a;IL-6;Complications;

Countries

China

Contacts

Public ContactHaihong Deng

The First People's Hospital of Zhaoqing

gzdhh@163.com+86 135 8057 4088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026